Dare Bioscience Inc
DARE2.390USD
-0.030-1.24%
Market hours （ET）Quotes delayed by 15 min
21.15MMarket Cap
LossP/E TTM
More Details of Dare Bioscience Inc Company
Dare Bioscience, Inc. is a biopharmaceutical company committed to advancing products for women's health. XACIATO, the Company's United States Food and Drug Administration (FDA)-approved product, vaginal gel 2%, a lincosamide antibacterial indicated for the treatment of bacterial vaginosis in female patients 12 years of age and older, which is under a global license agreement with Organon. Its clinical-stage programs include Ovaprene; Sildenafil Cream, 3.6%; DARE-HRT1; DARE-VVA1; DARE-CIN; DARE-PDM1; DARE-204 and DARE-214, and DARE-FRT1 and DARE-PTB1. Its pre-clinical stage programs include DARE-LARC1, DARE-LBT, DARE-GML, DARE-RH1 and DARE-PTB2. Ovaprene, is a hormone-free monthly intravaginal contraceptive. Sildenafil Cream, 3.6%, is a cream formulation of sildenafil, the active ingredient in Viagra, to treat female sexual arousal disorder (FSAD). DARE-HRT1, is a combination bio-identical estradiol and progesterone intravaginal ring for menopausal hormone therapy.
Company Info
Ticker SymbolDARE
Company nameDare Bioscience Inc
IPO dateApr 10, 2014
CEOMs. Sabrina Martucci Johnson
Number of employees21
Security typeOrdinary Share
Fiscal year-endApr 10
Address3655 Nobel Dr Ste 260
CitySAN DIEGO
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code92122-1050
Phone18589267655
Websitehttps://www.darebioscience.com/
Ticker SymbolDARE
IPO dateApr 10, 2014
CEOMs. Sabrina Martucci Johnson
Company Executives
Name
Name/Position
Position
Shareholding
Change
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
80.17K
--
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
859.00
--
Mr. Gregory W. (Greg) Matz, CPA
Mr. Gregory W. (Greg) Matz, CPA
Independent Director
Independent Director
42.00
--
Dr. Robin J. Steele, J.D.
Dr. Robin J. Steele, J.D.
Independent Director
Independent Director
--
--
Ms. Jessica D. Grossman, M.D.
Ms. Jessica D. Grossman, M.D.
Independent Director
Independent Director
--
--
Dr. Susan L. Kelley, M.D.
Dr. Susan L. Kelley, M.D.
Independent Director
Independent Director
--
--
Ms. Mardee Haring-layton
Ms. Mardee Haring-layton
Chief Accounting Officer
Chief Accounting Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Sabrina Martucci Johnson
Ms. Sabrina Martucci Johnson
President, Chief Executive Officer, Secretary, Director
President, Chief Executive Officer, Secretary, Director
80.17K
--
Dr. William H. (Bill) Rastetter, Ph.D.
Dr. William H. (Bill) Rastetter, Ph.D.
Independent Chairman of the Board
Independent Chairman of the Board
859.00
--
Mr. Gregory W. (Greg) Matz, CPA
Mr. Gregory W. (Greg) Matz, CPA
Independent Director
Independent Director
42.00
--
Dr. Robin J. Steele, J.D.
Dr. Robin J. Steele, J.D.
Independent Director
Independent Director
--
--
Ms. Jessica D. Grossman, M.D.
Ms. Jessica D. Grossman, M.D.
Independent Director
Independent Director
--
--
Dr. Susan L. Kelley, M.D.
Dr. Susan L. Kelley, M.D.
Independent Director
Independent Director
--
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Wed, Jul 2
Updated: Wed, Jul 2
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.71%
AMH Equity, Ltd.
1.86%
Geode Capital Management, L.L.C.
1.08%
Johnson (Sabrina Martucci)
0.91%
Renaissance Technologies LLC
0.80%
Other
91.65%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
3.71%
AMH Equity, Ltd.
1.86%
Geode Capital Management, L.L.C.
1.08%
Johnson (Sabrina Martucci)
0.91%
Renaissance Technologies LLC
0.80%
Other
91.65%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
5.35%
Hedge Fund
2.67%
Individual Investor
1.57%
Investment Advisor
1.31%
Other
89.10%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
65
970.65K
10.97%
-563.62K
2025Q1
68
970.95K
11.06%
-575.66K
2024Q4
68
920.93K
10.59%
-490.26K
2024Q3
68
799.08K
9.32%
-543.90K
2024Q2
73
745.25K
8.79%
-561.64K
2024Q1
76
712.54K
8.77%
-587.68K
2023Q4
81
694.22K
8.59%
-632.09K
2023Q3
78
1.22M
15.10%
+433.61K
2023Q2
79
709.35K
9.92%
-136.92K
2023Q1
79
741.09K
10.44%
-105.15K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
328.33K
3.71%
+39.70K
+13.76%
Mar 31, 2025
AMH Equity, Ltd.
164.30K
1.86%
+14.30K
+9.53%
Mar 31, 2025
Geode Capital Management, L.L.C.
95.91K
1.08%
+3.25K
+3.51%
Mar 31, 2025
Johnson (Sabrina Martucci)
80.17K
0.91%
+1.00
+0.00%
Apr 17, 2025
Renaissance Technologies LLC
70.59K
0.8%
+1.90K
+2.77%
Mar 31, 2025
Susquehanna International Group, LLP
58.16K
0.66%
+17.58K
+43.32%
Mar 31, 2025
Walters-Hoffert (Lisa)
36.96K
0.42%
--
--
Apr 17, 2025
State Street Global Advisors (US)
23.52K
0.27%
--
--
Mar 31, 2025
UBS Financial Services, Inc.
21.72K
0.25%
-10.30K
-32.18%
Mar 31, 2025
Steele Robin Joan
20.52K
0.23%
+1.00
+0.00%
Apr 17, 2025
View more
Related ETFs
Updated: Sat, Aug 2
Updated: Sat, Aug 2
Name
Proportion
iShares Micro-Cap ETF
0%
iShares Core S&P Total U.S. Stock Market ETF
0%
iShares Micro-Cap ETF
Proportion0%
iShares Core S&P Total U.S. Stock Market ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Jun 27, 2024
Merger
12<1
Jun 27, 2024
Merger
12<1
Jun 27, 2024
Merger
12<1
Jun 27, 2024
Merger
12<1
Date
Type
Ratio
Jun 27, 2024
Merger
12<1
Jun 27, 2024
Merger
12<1
Jun 27, 2024
Merger
12<1
Jun 27, 2024
Merger
12<1
